# Regulation of B cell Responses in SLE and Other Autoimmune Diseases

> **NIH NIH U19** · EMORY UNIVERSITY · 2024 · $234,750

## Abstract

Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease generated by abnormal
B cell function that induces pathogenic autoantibodies. Our lab has previously defined multiple B
cell abnormalities in SLE including the recent definition of an extrafollicular (EF) pathway
responsible for the generation of pathogenic DN2 effector B cells and the characterization of their
epigenetic programs. During the initial 4 years of this ACE cycle, we demonstrated that EF
reactions are enhanced in severe black SLE patients by hyper-responsiveness to TLR7
stimulation. Notably, we also showed that naïve-derived EF pathogenic autoimmune responses
are also strongly induced in patients with severe COVID-19 infections. Other studies from our
ACE center have identified additional complexity in the diversity of human effector and memory
B cells and their contribution to different immune responses and SLE pathogenesis and
suggested the contributions of B cell endotypes to distinct autoreactive and protective B cell
responses in SLE. However, the diversity of effector and memory B cell populations; their
segregation into disease endotypes; their molecular regulation; and their contributions to disease
pathogenesis remain to be understood. In this Principal Project, we will address these knowledge
gaps through two specific Aims. In Aim 1, we will characterize the diversity and molecular
regulatory programs of effector B cells in SLE using multi-spectral flow cytometry (MSFCM) and
single cell multi-omics (SCMO). Studies will be performed with total B cells as well as antigen-
specific B cells in blood, lymph nodes and Lupus kidneys. In Aim 2, we will study the diversity of
memory B cells in SLE and their derivation through germinal center dependent and independent
pathways and their regulatory programs using blood and lymph nodes. Combined with the
Collaborative and Pilot Project, our studies will contribute original insight into the diversity and
regulation of B cells in SLE, shed light into critical pathogenic processes, and identify cellular and
molecular diagnostic candidates and new targets for precision therapies. In sum, this Project will
enhance our ability to recognize SLE clusters with separate pathogenic mechanisms and
responses to therapy in SLE in general, and more particularly in the underserved Black SLE
population.
.

## Key facts

- **NIH application ID:** 10845043
- **Project number:** 2U19AI110483-11
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Ignacio E. Sanz
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $234,750
- **Award type:** 2
- **Project period:** 2014-05-01 → 2029-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10845043

## Citation

> US National Institutes of Health, RePORTER application 10845043, Regulation of B cell Responses in SLE and Other Autoimmune Diseases (2U19AI110483-11). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10845043. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*